Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the impact of bethanechol therapy on R0
resection rates. The safety objective will be assessment of the safety and tolerability of
bethanechol in combination with gemcitabine and nab-paclitaxel. The exploratory objective
will be to evaluate genomic biomarkers associated with parasympathetic stimulation in
pancreatic cancer, and the ability to reduce tumor growth rate.